Minority swarm

7 April 2006 By Rob Cox

That s because squeezeouts, like NovartisChiron this week, follow relatively consistent patterns that savvy investors can exploit. Many variables that determine premiums can be assessed easily. One big one, though the strength of independent directors cannot.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)